Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients

Next Previous
Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SAT 3247 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms BASECAMP
  • Sponsors Satellos Bioscience

Most Recent Events

  • 29 Jun 2026 According to a Satellos Bioscience media release, Phase 2 BASECAMP and TRAILHEAD studies ongoing in DMD with additional data expected in 2H 2026.
  • 15 May 2026 According to a Satellos Bioscience media release, eleven clinical trial sites in this BASECAMP study are currently active and remaining planned sites to be activated throughout second quarter of 2026. Company is on track to complete the enrollment in third quarter of 2026.
  • 27 Mar 2026 According to a Satellos Bioscience media release, Enrollment in this trial anticipated to complete in the third quarter of 2026 with top-line data expected in the fourth quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top